Цитирование
Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial. // The Lancet Haematology. – URL: https://www.sciencedirect.com/science/article/pii/S2352302626002012?dgcid=rss_sd_all
Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial. The Lancet Haematology. https://www.sciencedirect.com/science/article/pii/S2352302626002012?dgcid=rss_sd_all
“Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial.” The Lancet Haematology.
@article{article68517,
title = {Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial},
journal = {The Lancet Haematology},
url = {https://www.sciencedirect.com/science/article/pii/S2352302626002012?dgcid=rss_sd_all}
}